Results 271 to 280 of about 7,150,903 (384)
A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression
Molecular Oncology, EarlyView.Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote +8 morewiley +1 more sourceAdaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism
Molecular Oncology, EarlyView.Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch +16 morewiley +1 more sourceInterim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
, 2019 Elizabeth Page, Elizabeth Bancroft, Mark N. Brook, Melissa Assel, Mona Hassan Al Battat, Sarah Thomas, Natalie Taylor, Anthony Chamberlain, Jennifer Pope, Holly Ní Raghallaigh, D. Gareth Evans, Jeanette Rothwell, Lovise Mæhle, Eli Marie Grindedal, Paul A. James, Lyon Mascarenhas, Joanne McKinley, Lucy Side, Tessy Thomas, Christi J. van Asperen, Hans F. A. Vasen, Lambertus A. Kiemeney, Janneke Ringelberg, Thomas D. Jensen, Palle Jørn Sloth Osther, Brian T. Helfand, Elena Genova, Rogier A. Oldenburg, Cezary Cybulski, Dominika Wokołorczyk, Kai‐Ren Ong, Camilla Huber, Jimmy Lam, Louise Taylor, Mónica Salinas, Lídia Feliubadaló, Jan C. Oosterwijk, Wendy van Zelst-Stams, Jackie Cook, Derek J. Rosario, Susan M. Domchek, Jacquelyn M. Powers, Saundra S. Buys, Karen O’Toole, Margreet G.E.M. Ausems, Rita K. Schmutzler, Kerstin Rhiem, Louise Izatt, Vishakha Tripathi, Manuel R. Teixeira, Marta Cardoso, William D. Foulkes, Armen Aprikian, Heleen van Randeraad, Rosemarie Davidson, Mark Longmuir, Mariëlle Ruijs, Apollonia T.J.M. Helderman van den Enden, Muriel A. Adank, Rachel Williams, Lesley Andrews, Declan G. Murphy, Dorothy Halliday, Lisa Walker, Annelie Liljegren, Stefan Carlsson, Ashraf Azzabi, Irene Jobson, Catherine Morton, Kylie Shackleton, Katie Snape, Helen Hanson, Marion Harris, Marc Tischkowitz, Amy Taylor, Judy Kirk, Rachel Susman, Rakefet Chen‐Shtoyerman, Allan D. Spigelman, Nicholas Pachter, Munaza Ahmed, Teresa Ramón y Cajal, Janez Žgajnar, Carole Brewer, Neus Gadea, Angela F. Brady, Theo van Os, David Gallagher, Oskar T. Johannsson, Alan Donaldson, Julian Barwell, Nicola Nicolai, Eitan Friedman, Elias Obeid, Lynn Greenhalgh, Vedang Murthy, Lucia Copáková, Sibel Saya, John McGrath, Peter Cooke +99 moreopenalex +1 more sourcePatient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
Molecular Oncology, EarlyView.This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert +16 morewiley +1 more sourceSupplementary Table S2 from Mailing Vaginal or Urine Self-Sampling Kits versus Conventional Invitation Letters: A Randomized Trial to Assess the Effect on Cervical Cancer Screening Attendance
Caroline Lefeuvre, Hélène De Pauw, Nina Dhollander, Anne-Sophie Le Duc-Banaszuk, Adeline Pivert, Micheline Boudet, Aline Lebon, Johane Le Goff, Franck Rexand-Galais, Alexandra Ducancelle, Marc Arbyn +10 moreopenalex +1 more sourcePredictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman +17 morewiley +1 more sourceFeasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance
Molecular Oncology, EarlyView.Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis +11 morewiley +1 more source
